Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy
Protocol ID
Firefly-2
Disease (Sub Disease)
Low-Grade Glioma
Diagnosis Stage
Newly diagnosed
Location
NSW, SA, NZ
Sponsor
Day One Biopharmaceuticals, Inc.
Collaborators
SIOPe Brain Tumor Group LOGGIC Consortium
Links
Trial Status
Open
Sites
Starship Hospital
Sydney Children's Hospital
Women's and Children's Hospital
The Children's Hospital at Westmead
Sydney Children's Hospital
Women's and Children's Hospital
The Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 25 Years
International registry ID's
NCT05566795
| Study Title | A Phase 3 Randomized International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients With Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy |
|---|---|
| Protocol ID | Firefly-2 |
| Disease (Sub Disease) | Low-Grade Glioma |
| Diagnosis Stage | Newly diagnosed |
| Location | NSW / SA / NZ |
| Sponsor | Day One Biopharmaceuticals, Inc. |
| Collaborators | SIOPe Brain Tumor Group LOGGIC Consortium |
| Links | https://clinicaltrials.gov/ct2/show/NCT05566795 |
| Trial Status | Open |
| Trial Open Date | 19/05/2023 |
| Sites | Starship Hospital / Sydney Children's Hospital / Women's and Children's Hospital/ The Children's Hospital at Westmead |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 25 Years |
| International registry ID's | NCT05566795 |